Saltar al contenido
Merck

SML1088

SRPIN340

≥98% (HPLC)

Sinónimos:

(SRPIN)340, N-[2-(1-Piperidinyl)-5-(trifluoromethyl)phenyl]-4-pyridinecarboxamide

Iniciar sesión para ver los precios por organización y contrato.

Seleccione un Tamaño


Acerca de este artículo

Fórmula empírica (notación de Hill):
C18H18F3N3O
Número CAS:
Peso molecular:
349.35
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
51111800
MDL number:
Assay:
≥98% (HPLC)
Form:
powder
Quality level:
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarle
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarle

Nombre del producto

SRPIN340, ≥98% (HPLC)

InChI

1S/C18H18F3N3O/c19-18(20,21)14-4-5-16(24-10-2-1-3-11-24)15(12-14)23-17(25)13-6-8-22-9-7-13/h4-9,12H,1-3,10-11H2,(H,23,25)

SMILES string

O=C(C1=CC=NC=C1)NC2=C(N3CCCCC3)C=CC(C(F)(F)F)=C2

InChI key

DWFGGOFPIISJIT-UHFFFAOYSA-N

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 20 mg/mL, clear

storage temp.

2-8°C

Quality Level

Categorías relacionadas

Application

SRPIN340 has been used as a serine-arginine protein kinase (SRPK) inhibitor to identify if SRPK can phosphorylate the E3 ubiquitin ligase RNF12 ser/arg (SR)-motifs in vivo.

Biochem/physiol Actions

SRPIN340 is a cell-permeable, specific and potent inhibitor of Serine-Arginine-Rich Protein Kinase (SRPK) that down-regulates SRp75 and inhibits expression of Sindbis, hepatitis C virus (HCV), HIV, and cytomegalovirus viruses. SRPIN340 appears to be most effective for inhibiting acutely replicating viruses. SRPIN340 suppresses Vegf expression and attenuated choroidal neovascularization (CNV) formation in mice model.
SRPIN340 is a cell-permeable, specific and potent inhibitor of Serine-Arginine-Rich Protein Kinase (SRPK).
SRPIN340 is an isonicotinamide compound. It protects cardiomyocytes against hydrogen peroxide (H2O2) induced oxidative damage by serine-arginine protein kinase 1/2 (SRPK1/2) inhibition-mediated protein kinase B (AKT) activation.

Clase de almacenamiento

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Zhenyu Dong et al.
Molecular vision, 19, 536-543 (2013-04-06)
To investigate the applicability of serine/arginine-rich protein kinase (SRPK)-specific inhibitor, SRPIN340, for attenuation of choroidal neovascularization (CNV) formation using a mouse model. Laser photocoagulation was performed to induce CNV in C57BL/6J mice, followed by intravitreal injection of SRPIN340 or vehicle.
Jian Huang et al.
Biochemical and biophysical research communications, 510(1), 97-103 (2019-01-22)
SRPIN340, a selective serine-arginine protein kinase 1/2 (SRPK1/2) inhibitor, has been shown to have antiviral and anti-angiogenesis effects. However, its role in the heart is unknown. The present study explored the role of SRPIN340 in myocardial protection and the related
Yasuhiro Mimura et al.
Journal of cell science, 129(22), 4200-4212 (2016-11-02)
Lamin B receptor (LBR), an inner nuclear membrane (INM) protein, contributes to the functional integrity of the nucleus by tethering heterochromatin to the nuclear envelope. We have previously reported that the depletion of embryonic large molecule derived from yolk sac
Alzahraa A M Fergany et al.
Recent patents on anti-cancer drug discovery, 15(4), 293-305 (2020-09-10)
RNA splicing, a fundamental step in gene expression, is aimed at intron removal and ordering of exons to form the protein's reading frame. This review is focused on the role of RNA splicing in cancer biology; the splicing abnormalities that
Hugues de Boussac et al.
Haematologica, 105(3), 784-795 (2019-07-11)
Multiple myeloma (MM) account for approximately 10% of hematological malignancies and is the second most common hematological disorder. Kinases inhibitors are widely used and their efficiency for the treatment of cancers has been demonstrated. Here, in order to identify kinases

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico